Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada

MT Newswires Live

07/09

Teva Pharmaceutical Industries (TEVA) said Thursday it has signed a license and commercialization agreement with Samsung Bioepis for Opuviz, an aflibercept biosimilar referencing Eylea, in Canada.

Samsung Bioepis will handle product registration and manufacturing, while Teva Canada will lead commercialization.

Opuviz was approved by Health Canada in October 2025 for several eye conditions, including wet age-related macular degeneration and diabetic macular edema.

Teva said the deal strengthens its biosimilars portfolio in Canada and expands its ophthalmology presence.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2650992439"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2650992439\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2650992439?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650992439","market":"us","top_or_hot":-1,"title":"Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries (TEVA) said Thursday it has signed a license and commercialization agreement with Samsung Bioepis for Opuviz, an aflibercept biosimilar referencing Eylea, in Canada.</p><p>Samsung Bioepis will handle product registration and manufacturing, while Teva Canada will lead commercialization.</p><p>Opuviz was approved by Health Canada in October 2025 for several eye conditions, including wet age-related macular degeneration and diabetic macular edema.</p><p>Teva said the deal strengthens its biosimilars portfolio in Canada and expands its ophthalmology presence.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-07-09 20:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries (TEVA) said Thursday it has signed a license and commercialization agreement with Samsung Bioepis for Opuviz, an aflibercept biosimilar referencing Eylea, in Canada.</p><p>Samsung Bioepis will handle product registration and manufacturing, while Teva Canada will lead commercialization.</p><p>Opuviz was approved by Health Canada in October 2025 for several eye conditions, including wet age-related macular degeneration and diabetic macular edema.</p><p>Teva said the deal strengthens its biosimilars portfolio in Canada and expands its ophthalmology presence.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650992439","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650992439","pubTimestamp":1783600660,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical Industries (TEVA) said Thursday it has signed a license and commercialization agreement with Samsung Bioepis for Opuviz, an aflibercept biosimilar referencing Eylea, in Canada.Sams","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","EMXC":"iShares MSCI Emerging Markets ex China ETF","BK4504":"桥水持仓","BK4566":"资本集团","BK4007":"制药","BK4588":"碎股","BK4550":"红杉资本持仓","TEVA":"梯瓦制药","IEMG":"iShares Core MSCI Emerging Markets ETF","BK4585":"ETF&股票定投概念","BK4596":"哈里斯概念","BK4557":"大麻股","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4581":"高盛持仓","BK4559":"巴菲特持仓"},"translate_title":"梯瓦与三星Bioepis合作在加拿大商业化Eylea生物仿制药Opuviz","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1,"EMXC":1.5,"IEMG":1.5},"content_text":"Teva Pharmaceutical Industries (TEVA) said Thursday it has signed a license and commercialization agreement with Samsung Bioepis for Opuviz, an aflibercept biosimilar referencing Eylea, in Canada.Samsung Bioepis will handle product registration and manufacturing, while Teva Canada will lead commercialization.Opuviz was approved by Health Canada in October 2025 for several eye conditions, including wet age-related macular degeneration and diabetic macular edema.Teva said the deal strengthens its biosimilars portfolio in Canada and expands its ophthalmology presence.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}